The main objective is to determine the medical fate (transplanted or not and living or deceased), of patients with Severe, fulminating acute liver failure in the public hospitals of paris.
Severe, fulminating acute liver failure is a rare but serious disease. The overall prognosis has improved in recent years thanks to advances in medical management and liver transplantation. However, the epidemiology of this disease in France, the survival with or without liver transplantation of these patients and the factors that can influence this survival are not well known. The main objective is to determine the medical fate (transplanted or not and living or deceased), of patients with Severe, fulminating acute liver failure in the public hospitals of paris (APHP). The data will come from the APHP Health Data Warehouse
Study Type
OBSERVATIONAL
Enrollment
18,000
Paul Brousse Hospital
Villejuif, France
The main objective is to determine the medical fate (transplanted or not and living or deceased), of patients with Severe and fulminating acute hepatic failure within AP-HP hospitals
Patient status 1 month after diagnosis of this episode (alive or dead with or without transplantation)
Time frame: 1 month from the diagnosis of this episode
Epidemiology of Severe and fulminating acute hepatic failure
Sex Ratio M / F and cause of liver failure
Time frame: Baseline
Cause of death
Cause of death
Time frame: From date of inclusion until the date of death from any cause, assessed up to 9 years
Analysis of Clinical Pathway
Identification of the different services visited
Time frame: up to 1month after the diagnosis of this episode
Reasons for new hospitalizations with an admission date within 6 months after the diagnosis this episode
Identification by the usual code of the new hospitalization, consecutive to the episode
Time frame: within 6 months after the diagnosis this episode
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.